Latest in bladder cancer with FGFR 2 and 3 mutations

Bookmark and Share
Published: 24 Sep 2020
Views: 1506
Dr Yohann Loriot and Dr Scott Tagawa

Dr. Loriot and Dr. Tagawa spoke to ecancer in a stimulating expert to expert discussion about the FGFR-2,3 Bladder Cancer and the most important clinical updates regarding it from ESMO 2020.

Dr. Tagawa initially pointed out the key updates regarding this cancer and then moved on to explaining the challenges faced by clinicians in detecting the FGFR- 2,3 bladder cancer and how to overcome them.

He then highlighted some points in terms of disease management and the benefits of early detection.

Both the participants further discussed the non-invasive type of this cancer and how to detect that.

Dr. Loriot talked about targeted therapy and discussed how to overcome resistance in bladder cancer by combination therapy with Dr. Tagawa.

Dr. Loriot in the end, wrapped it up by mentioning biomarkers in the JAVELIN study and Dr. Tagawa explained the potential implications of the results from this study.

Read related news here.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).